Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Octreotide - Chiasma

Next Previous
Search
Drug Profile

Octreotide - Chiasma

Alternative Names: Chiasma Investigational Product 1; CHIP-1; Mycapssa; Octreolin; Octreotide acetate - Chiasma; Oral Octreotide; RG3806

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiasma
  • Developer Amryt Pharma; Chiasma
  • Class Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies; Indoles; Somatostatins
  • Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant carcinoid syndrome; Acromegaly
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acromegaly
  • No development reported Malignant carcinoid syndrome

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for phase-I development in malignant carcinoid syndrome in Unknown (PO)
  • 12 Apr 2023 Amryt Pharma has been acquired by Chiesi Farmaceutici
  • 19 Dec 2022 European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) adopts positive opinion on orphan disease designation for Octreotide for the treatment of Malignant carcinoid syndrome

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top